India Pharma Outlook Team | Tuesday, 29 July 2025
Novo Nordisk is doubling its India operations as it has launched a major expansion at its Global Business Services (GBS) hub in Bengaluru.
In July 2025, the company grew its workforce from 2,500 to over 4,500 employees to reflect its strategy for India as a global operational and innovation hub.
This year, Novo Nordisk plans to hire another 200-300 professionals in several major areas including AI, clinical research, regulatory affairs, and global operations. The purpose of these hires is to enable the company to leverage innovative capabilities and enable its global pharmaceutical pipeline from India more effectively.
Also Read: The Future of Green Chemistry in API Production
The country and culture's unique talent base and digital infrastructure have created a major force for short and long-term innovation expansion. The Bengaluru hub now does approximately 49% of the global safety assessments from Novo Nordisk, which underscores the crucial nature of India's role in the global operations of Novo Nordisk. Recent work, including harnessing AI to reduce total time to review medical documents from 40 hours to 40 minutes, is also providing large productivity gains for the company.
The company’s momentum in India also coincides with the local launch of its weight-loss drug Wegovy, further accelerating its footprint in the obesity and chronic care segment.
With its latest hiring push and increasing reliance on India for global functions, Novo Nordisk is clearly positioning the country as a cornerstone of its future growth and innovation strategy in the pharmaceutical industry.
